191 related articles for article (PubMed ID: 25059282)
1. Exploring pharmacological activities and signaling of morphinans substituted in position 6 as potent agonists interacting with the μ opioid receptor.
Ben Haddou T; Malfacini D; Calo G; Aceto MD; Harris LS; Traynor JR; Coop A; Schmidhammer H; Spetea M
Mol Pain; 2014 Jul; 10():48. PubMed ID: 25059282
[TBL] [Abstract][Full Text] [Related]
2. N-Phenethyl Substitution in 14-Methoxy-N-methylmorphinan-6-ones Turns Selective µ Opioid Receptor Ligands into Dual µ/δ Opioid Receptor Agonists.
Dumitrascuta M; Bermudez M; Ben Haddou T; Guerrieri E; Schläfer L; Ritsch A; Hosztafi S; Lantero A; Kreutz C; Massotte D; Schmidhammer H; Wolber G; Spetea M
Sci Rep; 2020 Mar; 10(1):5653. PubMed ID: 32221355
[TBL] [Abstract][Full Text] [Related]
3. Characterization of the complex morphinan derivative BU72 as a high efficacy, long-lasting mu-opioid receptor agonist.
Neilan CL; Husbands SM; Breeden S; Ko MC; Aceto MD; Lewis JW; Woods JH; Traynor JR
Eur J Pharmacol; 2004 Sep; 499(1-2):107-16. PubMed ID: 15363957
[TBL] [Abstract][Full Text] [Related]
4. Pharmacological investigations of N-substituent variation in morphine and oxymorphone: opioid receptor binding, signaling and antinociceptive activity.
Ben Haddou T; Béni S; Hosztafi S; Malfacini D; Calo G; Schmidhammer H; Spetea M
PLoS One; 2014; 9(6):e99231. PubMed ID: 24919067
[TBL] [Abstract][Full Text] [Related]
5. Characterization of a novel bivalent morphinan possessing kappa agonist and micro agonist/antagonist properties.
Mathews JL; Peng X; Xiong W; Zhang A; Negus SS; Neumeyer JL; Bidlack JM
J Pharmacol Exp Ther; 2005 Nov; 315(2):821-7. PubMed ID: 16076937
[TBL] [Abstract][Full Text] [Related]
6. Synthesis, Pharmacology, and Molecular Docking Studies on 6-Desoxo-N-methylmorphinans as Potent μ-Opioid Receptor Agonists.
Dumitrascuta M; Ben Haddou T; Guerrieri E; Noha SM; Schläfer L; Schmidhammer H; Spetea M
J Med Chem; 2017 Nov; 60(22):9407-9412. PubMed ID: 29053268
[TBL] [Abstract][Full Text] [Related]
7. Loss of TRPV1-expressing sensory neurons reduces spinal mu opioid receptors but paradoxically potentiates opioid analgesia.
Chen SR; Pan HL
J Neurophysiol; 2006 May; 95(5):3086-96. PubMed ID: 16467418
[TBL] [Abstract][Full Text] [Related]
8. Antinociception by spinal and systemic oxycodone: why does the route make a difference? In vitro and in vivo studies in rats.
Lemberg KK; Kontinen VK; Siiskonen AO; Viljakka KM; Yli-Kauhaluoma JT; Korpi ER; Kalso EA
Anesthesiology; 2006 Oct; 105(4):801-12. PubMed ID: 17006080
[TBL] [Abstract][Full Text] [Related]
9. Molecular Docking, Molecular Dynamics, and Structure-Activity Relationship Explorations of 14-Oxygenated N-Methylmorphinan-6-ones as Potent μ-Opioid Receptor Agonists.
Noha SM; Schmidhammer H; Spetea M
ACS Chem Neurosci; 2017 Jun; 8(6):1327-1337. PubMed ID: 28125215
[TBL] [Abstract][Full Text] [Related]
10. Effect of a 6-cyano substituent in 14-oxygenated N-methylmorphinans on opioid receptor binding and antinociceptive potency.
Spetea M; Greiner E; Aceto MD; Harris LS; Coop A; Schmidhammer H
J Med Chem; 2005 Jul; 48(15):5052-5. PubMed ID: 16033285
[TBL] [Abstract][Full Text] [Related]
11. Pharmacological characterization of novel synthetic opioids (NSO) found in the recreational drug marketplace.
Baumann MH; Majumdar S; Le Rouzic V; Hunkele A; Uprety R; Huang XP; Xu J; Roth BL; Pan YX; Pasternak GW
Neuropharmacology; 2018 May; 134(Pt A):101-107. PubMed ID: 28807672
[TBL] [Abstract][Full Text] [Related]
12. BU74, a complex oripavine derivative with potent kappa opioid receptor agonism and delayed opioid antagonism.
Husbands SM; Neilan CL; Broadbear J; Grundt P; Breeden S; Aceto MD; Woods JH; Lewis JW; Traynor JR
Eur J Pharmacol; 2005 Feb; 509(2-3):117-25. PubMed ID: 15733546
[TBL] [Abstract][Full Text] [Related]
13. Opioid agonist efficacy predicts the magnitude of tolerance and the regulation of mu-opioid receptors and dynamin-2.
Pawar M; Kumar P; Sunkaraneni S; Sirohi S; Walker EA; Yoburn BC
Eur J Pharmacol; 2007 Jun; 563(1-3):92-101. PubMed ID: 17349996
[TBL] [Abstract][Full Text] [Related]
14. Activation of delta-opioid receptor contributes to the antinociceptive effect of oxycodone in mice.
Yang PP; Yeh GC; Yeh TK; Xi J; Loh HH; Law PY; Tao PL
Pharmacol Res; 2016 Sep; 111():867-876. PubMed ID: 27496654
[TBL] [Abstract][Full Text] [Related]
15. Nociceptin/orphanin FQ receptor activation attenuates antinociception induced by mixed nociceptin/orphanin FQ/mu-opioid receptor agonists.
Khroyan TV; Polgar WE; Jiang F; Zaveri NT; Toll L
J Pharmacol Exp Ther; 2009 Dec; 331(3):946-53. PubMed ID: 19713488
[TBL] [Abstract][Full Text] [Related]
16. LPK-26, a novel kappa-opioid receptor agonist with potent antinociceptive effects and low dependence potential.
Tao YM; Li QL; Zhang CF; Xu XJ; Chen J; Ju YW; Chi ZQ; Long YQ; Liu JG
Eur J Pharmacol; 2008 Apr; 584(2-3):306-11. PubMed ID: 18353307
[TBL] [Abstract][Full Text] [Related]
17. In vivo characterization of (-)(-)MCL-144 and (+)(-)MCL-193: isomeric, bivalent ligands with mu/kappa agonist properties.
Mathews JL; Fulton BS; Negus SS; Neumeyer JL; Bidlack JM
Neurochem Res; 2008 Oct; 33(10):2142-50. PubMed ID: 18528756
[TBL] [Abstract][Full Text] [Related]
18. MGM-9 [(E)-methyl 2-(3-ethyl-7a,12a-(epoxyethanoxy)-9-fluoro-1,2,3,4,6,7,12,12b-octahydro-8-methoxyindolo[2,3-a]quinolizin-2-yl)-3-methoxyacrylate], a derivative of the indole alkaloid mitragynine: a novel dual-acting mu- and kappa-opioid agonist with potent antinociceptive and weak rewarding effects in mice.
Matsumoto K; Takayama H; Narita M; Nakamura A; Suzuki M; Suzuki T; Murayama T; Wongseripipatana S; Misawa K; Kitajima M; Tashima K; Horie S
Neuropharmacology; 2008 Aug; 55(2):154-65. PubMed ID: 18550129
[TBL] [Abstract][Full Text] [Related]
19. Pharmacological characterization of ATPM [(-)-3-aminothiazolo[5,4-b]-N-cyclopropylmethylmorphinan hydrochloride], a novel mixed kappa-agonist and mu-agonist/-antagonist that attenuates morphine antinociceptive tolerance and heroin self-administration behavior.
Wang YJ; Tao YM; Li FY; Wang YH; Xu XJ; Chen J; Cao YL; Chi ZQ; Neumeyer JL; Zhang A; Liu JG
J Pharmacol Exp Ther; 2009 Apr; 329(1):306-13. PubMed ID: 19136637
[TBL] [Abstract][Full Text] [Related]
20. Opioid peptide receptor studies. 14. Stereochemistry determines agonist efficacy and intrinsic efficacy in the [(35)S]GTP-gamma-S functional binding assay.
Xu H; Hashimoto A; Rice KC; Jacobson AE; Thomas JB; Carroll FI; Lai J; Rothman RB
Synapse; 2001 Jan; 39(1):64-9. PubMed ID: 11071711
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
